Alternative to Chemotherapy for Dogs with Osteosarcoma | Tammie Wahaus of ELIAS Animal Health #242

Dog Cancer Answers

ELIAS Animal Health CEO Tammie Wahaus returns to Dog Cancer Answers to talk about the company’s immunotherapy for dogs with osteosarcoma, which recently cleared an important milestone on the way to market.

ELIAS hopes their treatment will be accepted and used as a safe and appropriate alternative to chemotherapy in dogs with osteosarcoma. Instead of using chemotherapy to control metastasis, ELIAS uses the dog’s tumor to create a series of vaccines. Once the dog has the vaccinations, their immune system cells are harvested, taken back to the ELIAS labs, and spun up into an “army of angry killer T-cells” that are ready to murder that specific tumor!

It's truly personalized medicine, and it’s the first of its kind in animals OR people. Join us as we follow ELIAS progress on the way to market.

Listen to the first interview here: https://www.youtube.com/watch?v=YGIvyktfXlY

ELIAS Animal Health’s website: https://eliasanimalhealth.com/

Join our Facebook support group at https://dogcancer.com/support

Call [phone] to leave a question on our Listener Line for a future show!

Related Videos:

Tammie Wahaus’s first interview: https://www.youtube.com/watch?v=YGIvyktfXlY

Dr. Susan Ettinger, AKA Dr. Sue Cancer Vet, on HER2/NEU immunotherapy: https://www.youtube.com/watch?v=AEbcZVLoNeY

Chapters:

00:00 - Introduction: ELIAS Animal Health's Alternative to Chemotherapy for Dog Osteosarcoma

02:05 – Personalized Cancer Treatment for Dogs on the Horizon?

04:06 - Regulatory Landscape: Navigating the USDA Process

05:43 - Clinical Trial Results: Promising Alternatives to Traditional Chemotherapy

08:30 - Comparison with Chemotherapy: Effectiveness and Safety Insights

10:56 - Future Look: Will Carboplatin Continue to Be Standard of Care for Osteosarcoma?

12:45 - Safety Concerns: Cytokine Release Syndrome from Immunotherapy

19:30 – New Targets: Combining Immunotherapies, Adding Chemotherapy

20:02 – Metastatic Osteosarcoma: Adding a Checkpoint Inhibitor

22:08 – Experimental Use: Veterinarian Experience with Using ELIAS Under the Experimental License

26:15 – Human Vs. Animal Regulatory Approvals: What the FDA and USDA Do

28:41 - Human Application: Potential Implications for One Health Initiatives

33:40 - What Happens Next: Label to USDA Licensed Product and Commercial Launch

34:28 - Conclusion: Looking Forward to a Brighter Future in Canine Oncology

--

Get to know Tammie Wahaus: https://www.dogcancer.com/people/tammie-wahaus/

For more details, articles, podcast episodes, and quality education, go to the episode page: https://www.dogcancer.com/podcast/

Learn more about your ad choices. Visit megaphone.fm/adchoices